α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future

AV Terry Jr, PM Callahan - Neuropharmacology, 2020 - Elsevier
Schizophrenia is a devastating mental illness and its effective treatment is among the most
challenging issues in psychiatry. The symptoms of schizophrenia are heterogeneous …

[HTML][HTML] Muscarinic M1 receptors modulate working memory performance and activity via KCNQ potassium channels in the primate prefrontal cortex

VC Galvin, ST Yang, CD Paspalas, Y Yang, LE Jin… - Neuron, 2020 - cell.com
Working memory relies on the dorsolateral prefrontal cortex (dlPFC), where microcircuits of
pyramidal neurons enable persistent firing in the absence of sensory input, maintaining …

Association of cognitive and P50 suppression deficits in chronic patients with schizophrenia

L Xia, D Wang, J Wang, H Xu, L Huo, Y Tian… - Clinical …, 2020 - Elsevier
Objective Cognitive deficits are core symptoms of schizophrenia; however, their
pathophysiological mechanisms are still unclear. A sensory gating deficit, as reflected by …

Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement

MM Koola, SW Looney, H Hong, A Pillai, W Hou - Psychiatry Research, 2020 - Elsevier
Cognitive impairments are core features of schizophrenia and the best predictor of functional
outcome. Cholinergic system and alpha-7 nicotinic acetylcholine (α7nACh) receptors are …

[HTML][HTML] Schizophrenia in adults: Epidemiology and pathogenesis

BA Fischer, RW Buchanan - Waltham, MA: Wolters Kluwer, 2020 - medilib.ir
INTRODUCTION—Schizophrenia is among the most disabling and economically
catastrophic medical disorders. It is ranked by the World Health Organization as one of the …

GTS-21, an α7nAChR agonist, suppressed the production of key inflammatory mediators by PBMCs that are elevated in COPD patients and associated with impaired …

S Douaoui, R Djidjik, M Boubakeur, M Ghernaout… - Immunobiology, 2020 - Elsevier
Chronic obstructive pulmonary disease (COPD) is a lung inflammatory disease
characterized by progressive airflow limitation, chronic respiratory symptoms and frequent …

One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia

L Xia, L Liu, X Hong, D Wang, G Wei, J Wang… - …, 2020 - nature.com
The core features of schizophrenia (SCZ) include cognitive deficits and impaired sensory
gating represented by P50 inhibition deficits, which appear to be related to the α7 nicotinic …

P50 inhibition deficit in patients with chronic schizophrenia: Relationship with cognitive impairment of MATRICS consensus cognitive battery

L Xia, L Yuan, XD Du, D Wang, J Wang, H Xu… - Schizophrenia …, 2020 - Elsevier
Objective Cognitive impairment is a core symptom of schizophrenia (SCZ); however, its
pathophysiological mechanisms remain unclear. The sensory gating (SG) deficits reflected …

Alpha 7 nicotinic receptor agonist and positive allosteric modulators improved social and molecular deficits of MK-801 model of schizophrenia in rats

G Unal, H Bekci, A Cumaoglu, MB Yerer… - Pharmacology …, 2020 - Elsevier
Schizophrenia is a common psychiatric disease that cannot be fully treated with current
antipsychotic drugs. It has shown that glutamatergic NMDA receptor antagonists such as MK …

A randomized clinical trial of oxytocin or galantamine in schizophrenia: assessing the impact on behavioral, lexical, and self-report indicators of social affiliation

KR Dwyer, AM Andrea, CLG Savage… - Schizophrenia …, 2020 - academic.oup.com
Prior studies examining the impact of oxytocin on negative symptoms in schizophrenia have
yielded mixed results. The current study explored whether oxytocin can improve more …